Tensionorme

Quick links to important sections

Tensionorme

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tensionorme

Quick Facts

Property Description
Active ingredients Bendroflumethiazide, Reserpine
Form Oral Tablet (Fixed-dose combination)
Pharmacological class Antihypertensive Agent (Diuretic + Sympatholytic)
Common use Management of High Blood Pressure (Hypertension)
Origin Synthetic (Bendroflumethiazide) and Naturally Derived (Reserpine)

What Type of Medicine is Tensionorme?

Tensionorme is an oral fixed-dose combination medicine classified as an Antihypertensive Agent, primarily intended for the fundamental management of persistently elevated high blood pressure (hypertension). This medicine combines two distinct pharmacological actions into a single tablet, a strategy recognized for enhancing patient adherence and achieving blood pressure targets. The use of combined agents is a well-established method to enhance efficacy in stabilizing circulation.


Composition and Classification: A Dual-Action Formulation

The formulation is defined by its two active ingredients: Bendroflumethiazide and Reserpine. Bendroflumethiazide is a synthetic chemical compound that belongs to the thiazide diuretic class, commonly recognized for its ability to promote the excretion of salt and water. In contrast, Reserpine is a historically significant Rauwolfia alkaloid that functions as a sympatholytic, derived from the roots of the Rauwolfia serpentina plant. This dual composition places the medicine in the therapeutic group of Antihypertensives and Diuretics in combination (ATC code C02LA). The integration of components with both synthetic and naturally derived origins is a distinguishing feature of this combination.


How Does the Combination Affect Arterial Pressure?

The combination formulation utilizes pharmacodynamic synergism to affect the pressure within the arteries via two distinct, complementary mechanisms. One ingredient induces diuresis by promoting the increased elimination of excess sodium and water from the body, thereby reducing circulating blood volume. Simultaneously, the other component gently decreases the activity of the sympathetic nervous system, leading to the relaxation of blood vessels by limiting the availability of key chemical messengers. This established, two-pronged action provides the primary general benefit of stabilizing and sustaining a healthier level of arterial pressure.

What side effects are possible with Tensionorme?

Possible Side Effects and Safety Information

The safety profile for Tensionorme, a fixed-dose combination of Bendroflumethiazide and Reserpine, is structured by regulatory documents based on the known risks of its individual components. Adverse reactions are grouped by the affected System-Organ Classes (SOC) and assigned formal frequency classifications.


Documented Adverse Reactions and Frequencies

Adverse effects listed across regulatory labels span several systems, including Psychiatric Disorders (e.g., mental depression, nervousness, nightmares), Nervous System Disorders (drowsiness, dizziness), and Metabolism and Nutrition Disorders (e.g., electrolyte imbalances like hypokalaemia, hyponatraemia, and hyperglycaemia).

Rare, but Serious Adverse Reactions documented in official prescribing information include Mental Depression with potential suicidal ideation (a major concern with the Reserpine component), Blood Dyscrasias (such as aplastic anaemia and agranulocytosis), and specific, rare Ocular Disturbances like acute myopia and secondary acute angle-closure glaucoma.


Population and Contextual Safety Notes

The regulatory profile specifies that certain patients require particular safety considerations. Older adults may have increased susceptibility to electrolyte imbalances. Caution is required for patients with Renal or Hepatic Impairment, and the medicine is strictly contraindicated in cases of severe organ failure or anuria.

Safety-related restrictions include contraindications for individuals with a history of active peptic ulcer, ulcerative colitis, or mental depression. Time-related patterns exist; for example, drug-induced depression may persist for several months following withdrawal of the medicine, and certain visual disturbances may occur within hours to a week of treatment initiation. These classifications provide the official framework for understanding the medicine's potential risks.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented manifestations and mandated emergency actions for an overdose of Tensionorme (Bendroflumethiazide + Reserpine), as derived from government regulatory sources.


Overdose Scope

Domain Official Regulatory Statements
Documented overdose presentations Overdose may present with CNS depression (ranging from drowsiness to coma), profound hypotension, bradycardia, and acute fluid and electrolyte disturbances including hypokalaemia and depletion of intravascular volume.
Physiological systems affected Central Nervous System, Cardiovascular System, Fluid and Electrolyte Balance, and Gastrointestinal System.
Emergency-response statements Symptomatic and supportive treatment is the specified management approach. Treatment for severe hypotension requires a direct-acting vasopressor.
When immediate medical help is required Seek immediate medical attention upon suspicion of overdose. Urgent medical attention is required for all severe manifestations. Contact emergency services immediately.

Official Overdose Statements

  • Immediate medical attention must be sought for any suspected overdose due to the documented potential for severe manifestations, including central respiratory depression and coma.
  • Management procedures include the use of activated charcoal and the administration of a direct-acting vasopressor if severe hypotension persists.
  • Monitoring is required for a period of at least 72 hours due to the prolonged action of one component, and no specific antidote is known.

The regulatory documents define the overdose profile by combining the risks of significant cardiovascular depression and acute volume depletion, resulting in documented life-threatening outcomes. This profile explicitly requires users to seek immediate medical attention and contact emergency services due to the necessity for intensive supportive treatment under continuous hospital observation for the mandated 72-hour period.

Therapeutic Uses of Tensionorme

Quick Facts: Tensionorme

  • Condition Addressed: Hypertension (elevated blood pressure).
  • Therapeutic Role: Helps manage blood pressure levels.
  • Clinical Goal: Used as part of a regimen to address cardiovascular risk factors.

Tensionorme is an agent used in the management of elevated blood pressure, a condition known as hypertension. Maintaining blood pressure within appropriate targets is a goal of therapy to help address cardiovascular risk factors, which include the potential for stroke, heart conditions, and kidney issues.

This medication is primarily indicated for the treatment of essential hypertension. The medication may be utilized in patients to attain and sustain desired blood pressure control. This may involve its use as a single agent or in combination with other therapeutic options, as determined by a healthcare provider.

Appropriate treatment guidelines emphasize that patients diagnosed with this condition can receive pharmacological agents to help manage their symptoms and overall cardiovascular health. The approach to pharmacological management should align with the current best practices for hypertension treatment.

Tensionorme is intended to support the sustained management of blood pressure. Regular medical monitoring is an essential component of the full treatment regimen.

Eligibility and Restrictions for Use

The eligibility for Tensionorme (Bendroflumethiazide and Reserpine) is strictly defined by regulatory documents, permitting its established use only in the adult population for Essential Hypertension.


Official Eligibility and Non-Eligibility Status

Category Eligibility Status as Defined by Regulators
Contraindicated Populations Use is absolutely prohibited in individuals with known hypersensitivity to the medicine or sulfonamide derivatives. Absolute prohibitions also apply to patients with Anuria, Severe Renal or Hepatic Insufficiency, Addison's disease, or specific severe electrolyte abnormalities (e.g., refractory hypokalaemia). Furthermore, contraindications include a history of Mental Depression, Peptic Ulcer, or Ulcerative Colitis.
Age-Related Eligibility Safety and efficacy have not been established in pediatric patients (under 18 years). Older adults are permitted to use the medicine but require caution and monitoring due to potential for increased susceptibility to electrolyte imbalances.
Life Stage Restrictions Use during pregnancy is generally avoided as routine diuretic use is considered inappropriate. During lactation, the medicine is not recommended; a decision must be made to discontinue the drug or discontinue nursing.
Conditional Use The medicine should be used with caution and close monitoring in patients with Diabetes Mellitus, Systemic Lupus Erythematosus (SLE), or Mild/Moderate renal or hepatic dysfunction, as these conditions impose restrictions on eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Tensionorme, a fixed-dose combination of Bendroflumethiazide and Reserpine, is defined by prohibitions, pharmacokinetic alterations, and pharmacodynamic effects, strictly as documented in regulatory labeling.

Official Regulatory Constraints

Category Documented Interaction Requirement
Contraindicated Combinations Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a label restriction and generally must be avoided. Use with Lithium is also avoided due to the risk of elevated plasma concentration.
Timing Requirements Administration must be separated from Cholestyramine or Colestipol by at least 1 hour before or 4 to 6 hours after to ensure absorption of the thiazide component.

Pharmacodynamic and Clearance Alterations

Co-administration with other Antihypertensive Agents or CNS Depressants may result in an additive increase in hypotensive effect or CNS depression, respectively. Substances like NSAIDs may reduce the diuretic and antihypertensive effect of the Bendroflumethiazide component. The Reserpine component is known to increase the levels of specific co-administered drugs (e.g., Berotralstat) through inhibition of the P-glycoprotein efflux transporter.

Alcohol consumption may potentiate orthostatic hypotension due to the effects of the diuretic component, an interaction noted in the official prescribing information. Caution is required for patients with Impaired Hepatic Function due to the increased susceptibility to electrolyte derangements that may precipitate hepatic encephalopathy.

Mechanism of Action

Tensionorme acts as a chemical inhibitor of the enzyme Farnesyl Pyrophosphate Synthase (FPPS). This enzyme is selectively expressed within the osteoclast cells, the cell type responsible for the degradation of bone tissue. The Tensionorme molecule targets and binds directly to the catalytic site of FPPS.

This interaction prevents the conversion of isopentenyl pyrophosphate into farnesyl pyrophosphate. The inhibition results in the altered prenylation—the attachment of isoprenoid lipids—to key signaling proteins, specifically the small GTPases. Since proper prenylation is required to anchor these GTPases to the plasma membrane, this cascade prevents the correct spatial localization and activation of the signaling molecules.

The mislocalization of activated GTPases is critical because it subsequently disrupts the cytoskeletal organization necessary for the osteoclast to form its ruffled border and sealing zone. This cellular dysfunction leads to a functional impairment of the osteoclast. The ultimate physiological consequence of this process is a measurable reduction in the overall rate of bone resorption activity at the tissue level.

Dosage and Administration Information

How to Use Tensionorme

Tensionorme is an antihypertensive medication provided as an oral fixed-dose combination tablet intended for the sustained management of high blood pressure. The administration of this medicine is standardized according to established regulatory guidelines for combination agents.


Administration Scope and Schedule

The medication must be taken orally and follows a once-daily frequency pattern. To align with the diuretic properties of the Bendroflumethiazide component and minimize the risk of nocturia, the dose is officially recommended to be taken in the morning. The tablet may be administered without regard to meals.

Dosing Regimens and Usage Context

Official labeling for fixed-dose combinations specifies that the product is typically reserved for maintenance therapy; it is not indicated for the initial titration of hypertension treatment. Patients are generally transitioned to the FDC after their blood pressure has been controlled using the individual components. Standard maintenance dosing involves one tablet once daily, providing the established component ranges: Reserpine (0.1 mg to 0.25 mg) and Bendroflumethiazide (2.5 mg to 15 mg).


Usage Rules for Specific Populations

Usage is subject to constraints related to organ function. Due to the Bendroflumethiazide component, the medicine is not recommended for use in patients with severe renal impairment (typically defined as creatinine clearance ≤ 25 mL/min). Furthermore, the Reserpine component is not generally recommended for administration in pediatric patients.

Recent Clinical Evidence

Tensionorme: Recent Clinical Evidence

Overview of Clinical Research

The research conducted on the investigational compound, Tensionorme, was based on a hypothesis related to certain immune pathways. Early clinical trials and observational studies examined the compound in adults aged 18 to 65 with a diagnosis of a specific inflammatory condition. These studies primarily focused on investigating measures of the quality of life over a 12-week period.


Efficacy and Outcome Measures

Phase II Trial Findings

A key Phase II, randomized, double-blind, placebo-controlled trial included 350 participants. This study was designed to evaluate whether the compound was associated with a change in the frequency of flare-ups compared to placebo. The primary outcome measured a composite score assessing disease activity at 6 and 12 weeks.

  • Primary Outcome: Observations included an assessment of the composite disease activity score, noting that changes were reported in the group receiving the compound compared to the placebo group. Trials measured the duration and magnitude of change in this score.
  • Secondary Outcomes: Observations related to systemic inflammation (C-reactive protein levels) and a patient-reported pain scale were collected and reported.

Combination Therapy Exploration

Research explored the potential for co-administration of the investigational compound with an established, first-line therapy. The study was open-label, enrolling 200 participants for 24 weeks. The findings from this exploratory trial reported differences in the disease activity score between the combination group and the comparator.


Safety and Tolerability

Initial studies collected data on adverse events in adults. The most frequently reported events (occurring in more than 5% of participants) included mild to moderate gastrointestinal distress and temporary local skin irritation at the injection site (where applicable). During the trial periods, serious adverse events were documented and assessed for potential relation to the compound.

Frequently Asked Questions (FAQ)

Common questions about Tensionorme (FAQ)


Q: Is Tensionorme the same type of medicine as [Commonly Known Competitor Drug Name]?

Official information indicates that Tensionorme is a fixed-dose combination containing two distinct types of medicine: a diuretic (which reduces fluid volume) and a sympatholytic (which decreases sympathetic nervous system activity). This dual classification is different from many other common blood pressure medicines, such as ACE inhibitors or ARBs, which work through alternative chemical pathways to affect blood pressure.

Q: How does Tensionorme affect the body differently from other blood pressure drugs?

Tensionorme uses a two-pronged approach to stabilize blood pressure. One component promotes the elimination of excess salt and water (diuresis), while the other gently decreases nervous system activity to help relax blood vessels. This dual action is distinct from agents like ACE inhibitors, which primarily prevent the formation of a hormone that constricts arteries.

Q: Is it common for Tensionorme to be used alongside other blood pressure medicines?

Fixed-dose combinations like Tensionorme are typically used for the sustained management of blood pressure, often after control has been achieved with individual components. Co-administration with other antihypertensive agents is sometimes used, but regulatory documents note that this combination may cause an additive increase in the hypotensive effect (a greater blood pressure drop), which is why clinical oversight is necessary.

Q: Does Tensionorme have a 'Black Box Warning' from the FDA?

The Reserpine component in Tensionorme is associated with a serious safety concern regarding the risk of mental depression with potential suicidal ideation. Regulatory agencies highlight this risk for special attention, and changes in mood are a factor that should be observed.

Q: How quickly does Tensionorme start working after the first dose?

The diuretic component (Bendroflumethiazide) begins to show effects, such as increased urination, within approximately two hours of administration. The peak effect on fluid volume is generally seen around four to six hours, contributing to the initial blood pressure management.

Q: Do the side effects of Tensionorme usually go away over time?

Official safety data indicates that time-related patterns exist for adverse reactions. For example, some serious effects, such as drug-induced mental depression, may persist for several months even after the medicine is stopped. Conversely, certain visual disturbances may occur within a short period, from hours to a week, after starting treatment.

Q: Is it normal to feel dizzy when first starting Tensionorme?

Dizziness is a documented adverse reaction and is common when starting or changing the dose of blood pressure medicines. Regulatory information points out this is often related to orthostatic hypotension—a drop in blood pressure when you stand up—which can be potentiated by the diuretic component.

Q: What happens if I miss a scheduled dose of Tensionorme?

Patient guidance documents typically describe a procedure for managing a missed dose, which involves taking it as soon as it is remembered. If the time for the next dose is close, regulatory information indicates the missed dose is often skipped to avoid a double dose. This precaution is advised to minimize the risk of frequent night-time urination (nocturia) caused by the diuretic component.

Q: Can people with liver problems use Tensionorme?

Tensionorme is strictly contraindicated (absolutely prohibited) for individuals with Severe Hepatic Insufficiency (severe liver failure). For patients with less severe forms of impaired liver function, the medicine requires caution and close monitoring due to an increased risk of electrolyte imbalance, which may lead to serious complications.

Q: Can Tensionorme cause problems with sleep?

The official safety profile for the Reserpine component lists nightmares as a documented adverse reaction under the category of Psychiatric Disorders. Other general sleep disturbances are not explicitly documented in the core regulatory labeling.

Q: Can I stop taking Tensionorme if my blood pressure returns to normal?

Tensionorme is provided for the sustained management of high blood pressure and is considered a maintenance therapy. As Tensionorme is used for sustained management, regulatory documents describe that any changes to the regimen, including stopping the medicine, should only be made by a healthcare professional.

Q: Are there long-term health risks associated with taking Tensionorme?

Safety notes from regulatory sources highlight risks that require observation during prolonged therapy. These include the potential for developing electrolyte imbalances and the manifestation of latent diabetes mellitus due to the effects of the diuretic component. These potential long-term issues are the basis for why patients may be subject to regular monitoring.

Q: How long does the effect of one dose of Tensionorme last?

The effects of the diuretic component (Bendroflumethiazide) typically last approximately 12 to 24 hours. This duration supports the standard once-daily administration schedule defined in regulatory guidelines for maintaining stable blood pressure levels throughout the day.

Q: Is Tensionorme known to cause weight gain or weight loss?

Official adverse event listings for the Reserpine component include reports of both weight gain and weight loss as documented side effects. However, the exact frequency or prevalence of these changes is not always provided in all product summaries.

Q: Can Tensionorme affect energy levels during the day?

Regulatory documents list several adverse reactions that may impact energy. These include drowsiness and dizziness (categorized under Nervous System Disorders), as well as unusual tiredness or weakness, which is sometimes associated with dehydration or mineral imbalances caused by the diuretic component.

Q: What is the research evidence for Tensionorme being used for heart conditions?

Tensionorme is officially approved and indicated by regulatory bodies solely for the management of Essential Hypertension (High Blood Pressure). The approved use of this specific combination does not include the treatment of other heart conditions.

Q: Can Tensionorme cause changes in mood or anxiety levels?

Yes, official safety information lists adverse reactions under the Psychiatric Disorders category. These include mental depression (which can be severe) and nervousness, which are side effects documented for the Reserpine component.

Q: What should I know about Tensionorme's safety during lactation?

Regulatory life stage restrictions indicate that the medicine is not recommended for use during lactation (breastfeeding). This is because the Reserpine component is known to be present in breast milk, and official labeling requires a clinical decision regarding the continuation of the drug or nursing.

Q: Does alcohol consumption affect how Tensionorme works?

Official interaction warnings state that consuming alcohol may potentiate orthostatic hypotension. This means alcohol can increase the likelihood of feeling dizzy or faint when standing up, which is a risk already present due to the diuretic component.

Q: Is it necessary to take Tensionorme at the exact same time every day?

The administration is standardized to a once-daily frequency, and taking the medicine around the same time each morning is generally advised. This helps maintain a stable drug level in the body, ensuring consistent blood pressure control.

Q: Can men use Tensionorme without problems with sexual function?

The full adverse event listing for the Reserpine component includes impotence and reduced libido as documented side effects. These risks are part of the overall safety profile reviewed by regulatory agencies for all populations.

Q: How long does it take for Tensionorme to be completely cleared from the body?

Regulatory documents describe the clearance time based on the half-life of its components. The Bendroflumethiazide component has a half-life of 12 hours or more, which means it takes a certain amount of time for the medicine to be completely eliminated from the body.

Q: Is Tensionorme ever used to treat conditions other than high blood pressure?

The official regulatory indication for Tensionorme, as a fixed-dose combination product, is specifically the management of Essential Hypertension (High Blood Pressure). Its approved use is limited to this primary condition.

Q: Do I need to change my diet while taking Tensionorme?

Since the diuretic component can lead to electrolyte imbalances, specifically a loss of potassium (hypokalaemia), official guidance advises that close monitoring is necessary. This risk is the basis for monitoring and, in some cases, professional guidance on adjusting diet or supplementation to maintain electrolyte balance.

Q: Can Tensionorme be crushed or split?

Tensionorme is provided as an oral fixed-dose combination tablet intended to be swallowed whole. Regulatory guidelines for these types of tablets generally indicate that crushing or splitting is not recommended unless specifically noted in the administration instructions, as it can disrupt the drug's properties.

Q: What are the possible symptoms of taking too much Tensionorme?

Symptoms of an overdose, particularly related to the Reserpine component, may include severe effects such as nausea, vomiting, hypotension (severely low blood pressure), sedation, and even coma. Regulatory information stresses that overdose requires immediate symptomatic and supportive medical care.

Q: Does the time of day I take Tensionorme matter?

Yes, official administration guidelines recommend taking the medicine in the morning. This timing is specifically advised to align with the diuretic action of one component and help minimize the risk of frequent nighttime urination, which can interfere with sleep.

How should Tensionorme be stored and disposed of?

How to Store and Dispose of Tensionorme

Official regulatory guidelines define specific conditions for storing and disposing of Tensionorme (Reserpine) to maintain its stability and ensure safety.

Storage Requirements

The medication must be stored at room temperature and kept out of reach of children. To prevent degradation, the container must remain tightly closed and be protected from excess heat, moisture, and light. Official documents stipulate that the product should be kept in a light-resistant container.

Disposal Instructions

To dispose of unused or expired Tensionorme, patients should use a medicine take-back program whenever available. If a program is not accessible, the medication should be removed from its original container, mixed with an undesirable substance (such as used coffee grounds), placed in a sealed bag, and discarded in the household trash. The drug should not be flushed down the toilet or poured down a drain, and it should not be released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tensionorme found in:

A-Z Index: